Get Live Data

focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

  2. Share Prices
  3. Syncona Share Price
  4. Syncona Share News
  5. IN BRIEF: Syncona notes FDA acceptance of Autolus's BLA for obe-cel

Pin to quick picksSyncona Share News (SYNC)

Syncona Information

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 113.00
Bid: 112.20
Ask: 113.00
Change: -1.80 (-1.57%)
Spread: 0.80 (0.713%)
Open: 114.00
High: 114.20
Low: 112.80
Prev. Close: 114.80
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: Syncona notes FDA acceptance of Autolus's BLA for obe-cel

Mon, 22nd Jan 2024 12:19

Syncona Ltd - London-based investor in healthcare companies - The US Food & Drug Administration accepts Autolus Therapeutics PLC's biologics licence application for obe-cel for patients with relapsed/refractory adult B-cell acute lymphoblastic leukaemia. The FDA has set a target action date of November 16 for reviewing the application, Syncona says. Further, Autolus is on track to submit a marketing authorisation application to the EU's European Medicines Agency in the first half of 2024.

Syncona has an 18% stake in Autolus.

Current stock price: 117.05 pence, down 0.3% on Monday

12-month change: down 31%

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
31 Mar 2021 09:18

Syncona says Achilles stake leaps to GBP145 million value after IPO

Syncona says Achilles stake leaps to GBP145 million value after IPO

Read more
31 Mar 2021 07:41

Achilles Therapeutics prices IPO at $175m as Syncona keeps 27% stake

(Sharecast News) - Syncona portfolio biopharma company Achilles Therapeutics said its US initial public offering (IPO) will raise $175.5m (£127.8mln).

Read more
30 Mar 2021 16:01

DIRECTOR DEALINGS: Gym Group directors sell GBP1.8 million in shares

DIRECTOR DEALINGS: Gym Group directors sell GBP1.8 million in shares

Read more
26 Mar 2021 09:20

Syncona invests USD42 million into Gyroscope to have 54% stake

Syncona invests USD42 million into Gyroscope to have 54% stake

Read more
26 Mar 2021 07:59

Syncona invests £31m in Gyroscope

(Sharecast News) - Syncona has invested $42.3m (£31m) in Gyroscope Therapeutics as part of a $148m financing by the retinal gene therapy company.

Read more
25 Mar 2021 12:23

Syncona portfolio firm Achilles Therapeutics prices US share offering

Syncona portfolio firm Achilles Therapeutics prices US share offering

Read more
4 Mar 2021 12:46

TRADING UPDATES: Origin Enterprises loss slims; Amryt issues guidance

TRADING UPDATES: Origin Enterprises loss slims; Amryt issues guidance

Read more
2 Mar 2021 13:45

IN BRIEF: Syncona investee Achilles Therapeutics files for US IPO

IN BRIEF: Syncona investee Achilles Therapeutics files for US IPO

Read more
12 Feb 2021 16:24

IN BRIEF: Syncona's Gyroscope Reports Positive Results From GT005 Test

IN BRIEF: Syncona's Gyroscope Reports Positive Results From GT005 Test

Read more
11 Feb 2021 10:05

Syncona Net Asset Value Dips In Third Quarter, Invests More In Quell

Syncona Net Asset Value Dips In Third Quarter, Invests More In Quell

Read more
11 Feb 2021 07:56

Syncona makes decent progress in December quarter

(Sharecast News) - Healthcare investment company Syncona updated the market on its latest quarter on Thursday, reporting clinical, financial and operational progress across its portfolio in the three months ended 31 December.

Read more
10 Feb 2021 09:41

Syncona Investee Autolus Nets USD100 Million From ADS Offer

Syncona Investee Autolus Nets USD100 Million From ADS Offer

Read more
10 Feb 2021 09:31

Syncona upbeat on Autolus US public offering pricing

(Sharecast News) - Healthcare investor Syncona said on Wednesday that its portfolio company Autolus Therapeutics has priced its underwritten public offering in the United States at $7.00 per American depositary share (ADS).

Read more
8 Feb 2021 13:09

Syncona Investee Freeline Modifies Hemophilia Plan After FDA Feedback

Syncona Investee Freeline Modifies Hemophilia Plan After FDA Feedback

Read more
5 Feb 2021 08:20

Syncona Investee Achilles Reports Positive Trial Review, Mulling IPO

Syncona Investee Achilles Reports Positive Trial Review, Mulling IPO

Read more
5678910111213

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.